Biosphere Medical — Investor Presentation (January 2010)
25 slides from Biosphere Medical's investor presentation, Jan 11, 2010
Slide 1: BioSphere Medical January 2010
BioSphere’ Qiioverere January 2010
Slide 2: Safe Harbor
SAFE HARBOR This presentation contains statements about the Company’s future expectations, plans and prospects that constitute forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995, including statements concerning the Company’s strategic goals and objectives
Slide 3: Company Snapshot
COMPANY SNAPSHOT Embosphere - FDA 510(k) for hypervascularized tumors and AVMs 2000 2002 2005 2006 2007 2008 2009 Embosphere 510(k) UFE indication Sales Force expansion QuadraSphere 510(k) HepaSphere CE Mark - drug delivery of doxorubicin to treat HCC ACOG LEVEL A recommendation Distribution agreeme
Slide 4: Investment Considerations
INVESTMENT CONSIDERATIONS Platform technology applicable to multiple therapeutic areas with compelling market sizes Uterine fibroids (interventional gynecology); $650 million market (US, EMEA, China, Japan, Brazil) Primary liver cancer (interventional oncology); $380 million market for drug-eluting
Slide 5: Differentiated Proprietary Products – Dominant Market Share
DIFFERENTIATED PROPRIETARY PRODUCTS – DOMINANT MARKET SHARE EMBOSPHERE MICROSPHERES First embolic cleared by the FDA for UFE Most clinically studied spherical embolic Calibrated sphere/targeted delivery Hydrophilic/lubricious/non-aggregating Compressible and resilient formulation Positive polymer ch
Slide 6: Marketed Products and Pipeline
PRODUCT ACTUAL / PLANNED INDICATIONS PRECLINICAL CLINICAL MARKETED Embosphere Microspheres Uterine Fibroid Embolization HepaSphere / QuadraSphere Microspheres Hypervascularized tumors and AVMs HepaSphere Microspheres + Doxorubicin Hepatocellular Carcinoma (HCC) QuadraSphere Microspheres – US IDE sub
Slide 7: Current Therapeutic Focus; Pipeline
CURRENT THERAPEUTIC FOCUS; PIPELINE Interventional Gynecology – Treatment of benign uterine fibroids – Uterine Fibroid Embolization (UFE) Interventional Oncology – Treatment of malignant tumors through targeted vascular occlusion and drug delivery Interventional Urology – Treatment of benign prostat
Slide 8: Market for Women with Symptomatic Fibroids
MARKET FOR WOMEN WITH SYMPTOMATIC FIBROIDS Millions Millions Women 30-49 Years Old
Slide 9: Clinical Results of UFE
CLINICAL RESULTS OF UFE Uterus-sparing, safe and effective symptom relief (2003-2008) ACOG Level A Recommendation Reproducible quality-of-life outcomes FIBROID Registry (December 2005, January 2008) 5-year durability (November 2005) Fertility “Pregnancy possible after UFE” (January 2005, November 20
Slide 10: Patient - Provider - Supplier Perspectives
PATIENT - PROVIDER - SUPPLIER PERSPECTIVES DAYS DAYS HOSPITAL UFE performed in a cath lab, a lower cost venue than the operating room CMS 2010 reimbursement up 7.6% to ~ $6,413 per procedure Average contribution margin to hospital $2,860 vs. $163 for hysterectomy and $(9) for myomectomy INTERVENTION
Slide 11: Pioneer/Leader in Embolotherapy
PIONEER/LEADER IN EMBOLOTHERAPY Interventional Gynecology – Treatment of benign uterine fibroids – Uterine Fibroid Embolization (UFE) Interventional Oncology – Treatment of malignant tumors through targeted vascular occlusion and drug delivery Interventional Urology – Treatment of benign prostatic h
Slide 12: Building a Global Position in Interventional Oncology
BUILDING A GLOBAL POSITION IN INTERVENTIONAL ONCOLOGY ~24% of current embolic sales Growing global incidence of primary liver cancer (HCC) ~600,000 new cases worldwide each year Half WW incidence is in China Worldwide adoption of Embosphere Microspheres for multiple-treatment protocols Shipments to
Slide 13: Chemoembolization Is Standard of Care
“Chemoembolization is accepted worldwide as an effective treatment for patients with unresectable HCC and adequate preservation of liver function.” Brown, et al., Society of Interventional Radiology Position Statement on Chemoembolization of Hepatic Malignancies, JVIR 2006; 17(2):217-223. CHEMOEMBOL
Slide 14: HepaSphere/QuadraSphere – Drug Delivery
In vivo evaluation of drug release: Immunofluorescence showing doxorubicin released in the tissue surrounding the microspheres HEPASPHERE/QUADRASPHERE – DRUG DELIVERY Doxorubicin-loaded Microspheres* Source: Interventional News (Jan-Mar, 2007), p. 6. *CE Mark clearance for the delivery of doxorubici
Slide 15: HepaSphere/QuadraSphere in Liver Cancer Treatment (HiQUALITY) Protocol
HepaSphere/QuadraSphere in Liver Cancer Treatment (HiQUALITY) Protocol QuadraSphere loaded with doxorubicin vs. conventional transarterial chemoembolization (cTACE) with doxorubicin; current standard of care 200+ patients at 16 sites in the US, European Union and Brazil Primary endpoint/basis PMA fi
Slide 16: Clinical Basis for HiQUALITY Study
CLINICAL BASIS FOR HiQUALITY STUDY Maurizio Grosso, MD 34 patients with primary liver cancer demonstrated an objective tumor response of 79% at six months when treated with HepaSphere Microspheres loaded with doxorubicin Guido Poggi, MD Investigated new use for HepaSphere: With oxaliplatin for intra
Slide 17: Pioneer/Leader in Embolotherapy
PIONEER/LEADER IN EMBOLOTHERAPY Interventional Gynecology – Treatment of benign uterine fibroids – Uterine Fibroid Embolization (UFE) Interventional Oncology – Treatment of malignant tumors through targeted vascular occlusion and drug delivery Current Therapeutic Focus Interventional Urology – Treat
Slide 18: BPH Opportunity U.S. Only
Millions Estimated market opportunity if actively treated patients receive 1 embolization cycle +$800 million BPH OPPORTUNITY U.S. ONLY
Slide 19: BPH Preclinical Studies
MRI scan of the prostate (arrow) MRI scan of the prostate (arrow) 1 month prior to embolization with 500- after embolization with 500-700µm 700µm Embospheres Embospheres: 50% volume reduction Mild decrease in urethral stenosis after embolization Results: 3T MRI scans before and 1 month after emboliz
Slide 20: BPH Clinical Update
Clinical Studies Initial clinical results (2 patients using 300-500µm Embosphere) Each patient exhibited marked (40% and 24%, respectively, at one month, and 48% and 28%, respectively, at 6 months) reduction in prostate volume post procedure by MRI Both patients enjoyed improvement in symptoms with
Slide 21: Experienced Executive Leadership Team
EXPERIENCED EXECUTIVE LEADERSHIP TEAM Richard J. Faleschini, President and Chief Executive Officer American Medical Systems, Medtronic, Cordis Martin J. Joyce, Exec. Vice President, Chief Financial Officer Stratex Group, Serono, Millipore Melodie R. Domurad, PhD, Vice President of Regulatory, Medica
Slide 22: 2010 Strategic Priorities
2010 STRATEGIC PRIORITIES Interventional Gynecology Scale-up community health talks in 2010 to over ~200+ events Commence direct-to-employer education for UFE promoting the rapid return to work after a UFE procedure compared to surgical alternatives Interventional Oncology Based on the green light f
Slide 23: Financial Update
FINANCIAL UPDATE (In thousands, except per-share amounts) Sept 30, 2009 Dec 31, 2008 Cash, short- and long-term investments $18,566 $18,239 Total Assets $30,568 $30,228 Sept 30, 2009 Sept 30, 2008 Revenue $7,686 $7,198 Net Loss Applicable to Common Stockholders ($361) ($1,543) Basic and Diluted Net
Slide 24: Investment Considerations
INVESTMENT CONSIDERATIONS Platform technology applicable to multiple therapeutic areas with compelling market sizes Uterine fibroids (interventional gynecology); $650 million market (US, EMEA, China, Japan, Brazil) Primary liver cancer (interventional oncology); $380 million market for drug-eluting
Slide 25: BioSphere Medical
BioSphere’ Qiioverere January 2010
BioSphere Medical — Investor Presentation (January 2010) on 6ix